

## HST Evaluation Committee Interests Register

### Vutrisiran for treating hereditary transthyretin-related amyloidosis [ID5074]

Publication Date: 15 February 2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Marianna Fontana	Clinical Expert	Indirect	Advisor for Alnylam, Ionis, Intellia, NovoNordisk, ATTRalus, Pfizer, Caelum/Alexion, BridgBio all of whom are developing drugs for potential use in amyloidosis.	N/A	30/09/2022	N/A	It was agreed that the declaration would not prevent Professor Fontana from providing expert advice to the committee.
Professor Julian Gillmore	Clinical Expert	Indirect	Advisor for Alnylam, Ionis, Intellia, Astra-Zenica, ATTRalus, Pfizer, all of whom are developing drugs for potential use in ATTR amyloidosis.	N/A	30/09/2022	N/A	It was agreed that the declaration would not prevent Professor Gillmore from providing expert advice to the committee.